Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) had its price objective boosted by Citigroup from $70.00 to $74.00 in a research note published on Thursday morning,Benzinga reports. They currently have a buy rating on the stock. Several other equities analysts have also weighed in on the stock. Oppenheimer restated an “outperform” rating and set a $73.00 […]

Tarsus Pharmaceuticals (NASDAQ:TARS – Free Report) had its price objective raised by Oppenheimer from $63.00 to $65.00 in a research note published on Thursday,Benzinga reports. Oppenheimer currently has an outperform rating on the stock. Separately, William Blair raised shares of Tarsus Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th. One equities […]

X4 Pharmaceuticals (NASDAQ:XFOR – Free Report) had its target price trimmed by HC Wainwright from $5.00 to $1.50 in a research note released on Thursday morning,Benzinga reports. The brokerage currently has a buy rating on the stock. Separately, Stifel Nicolaus lowered their price target on shares of X4 Pharmaceuticals from $5.00 to $4.00 and set […]

Ligand Pharmaceuticals (NASDAQ:LGND – Free Report) had its price target increased by Royal Bank of Canada from $130.00 to $140.00 in a research note released on Tuesday,Benzinga reports. The brokerage currently has an outperform rating on the biotechnology company’s stock. Other analysts have also recently issued reports about the company. Oppenheimer upped their price target […]

Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) had its target price upped by stock analysts at Oppenheimer from $135.00 to $147.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has an “outperform” rating on the biotechnology company’s stock. Oppenheimer’s price target would suggest a potential upside of 21.24% from the stock’s […]